Skip to Main Content

In a potentially huge setback for Biogen (BIIB), a European regulatory panel signaled that it is unlikely to recommend the company’s controversial Alzheimer’s treatment should be approved. And while a final decision by the European Medicines Agency will not be known until next month, Wall Street is quickly discounting the possibility the medication will generate revenues from the vast European market.

The move comes amid intensifying pressure on Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment